Developer docs
API playgroundTry for free, no card

Search company profiles

Cybin

Full company profile

uuid025agn8

Namestring
Cybin
Legal namestring
Cybin Inc.
Websiteurl
cybin.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Helus Pharma (formerly Cybin Inc.) is a clinical-stage neuropsychiatric pharmaceutical company developing deuterated psychedelic-based therapeutics for mental health conditions. Founded in 2019 in Toronto, Canada, and publicly traded on Nasdaq and Cboe Canada under ticker HELP, the company operates two lead drug programs: HLP003, a deuterated psilocybin analog in Phase 3 clinical trials for adjunctive treatment of major depressive disorder (MDD), which has received FDA Breakthrough Therapy Designation, and HLP004, a deuterated DMT analog that has completed Phase 2 enrollment for generalized anxiety disorder (GAD). The company also retains SPL026, a synthetic DMT candidate acquired through the 2023 Small Pharma acquisition, which demonstrated a 7.35-point MADRS reduction versus placebo in Phase 2a trials.

The company's core technology platform is built on novel serotonergic agonists (NSAs)—synthetic molecules engineered to activate serotonin pathways believed to promote neuroplasticity—combined with proprietary drug delivery formulations designed to reduce inter-individual variability of acute effects and shorten clinic time. The intellectual property portfolio includes 350+ pending patent applications and 100+ granted patents protecting both the molecular architecture and delivery mechanisms. The FDA Breakthrough Therapy Designation for HLP003 provides an accelerated regulatory pathway, with Phase 3 APPROACH trial topline data expected in Q4 2026.

Helus Pharma is currently pre-revenue, operating across Canada, the United States, the United Kingdom, and Ireland, with a research collaboration with Imperial College London. The company maintains approximately $195 million in cash as of December 2025 with no financial debt, supplemented by a $100 million at-the-market equity program through Cantor Fitzgerald and a ~$50 million underwritten public offering completed in June 2026, providing approximately 21 months of runway against an ~$114 million annual burn. The intended go-to-market model upon regulatory approval involves traditional pharmaceutical wholesale distribution, specialty pharmacy networks, and direct physician engagement with healthcare providers and psychiatric clinics, with analyst coverage (Jefferies, HC Wainwright) maintaining Buy ratings.

Short descriptiontext

Helus Pharma (formerly Cybin Inc.) is a clinical-stage pharmaceutical company developing deuterated psilocybin and DMT analogs (HLP003, HLP004) as novel serotonergic agonists for major depressive disorder and generalized anxiety disorder, with FDA Breakthrough Therapy Designation and Phase 3 data expected Q4 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psychedelic therapeutics, neuropsychiatric drugs, serotonergic agonists, depression treatment, anxiety treatment
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neuropsychiatric Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Drug Sales
TypeOne Time License
Description

Currently pre-revenue. The company is a clinical-stage neuropsychiatry company developing psychedelic-based treatments for mental health conditions. If HLP003 and HLP004 receive regulatory approval, the company would generate revenue through prescription drug sales to patients with major depressive disorder and generalized anxiety disorder.

simplywall.st
2Future Licensing Royalties
TypeLicensing Royalties
Description

Potential licensing agreements for proprietary compounds and delivery technologies to pharmaceutical partners in different geographic regions.

simplywall.st
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cybin (operating as Helus Pharma) is a clinical-stage pharmaceutical company developing proprietary deuterated psilocybin and DMT analogs—branded HLP003 and HLP004—as adjunctive therapies for major depressive disorder and generalized anxiety disorder. The company also holds SPL026, a synthetic DMT candidate acquired from Small Pharma, and is advancing a proprietary drug delivery platform designed to reduce variability of acute effects and shorten in-clinic administration time.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ~23-point reduction in MADRS score at 12 months with 100% response rate and 71% remission rate in Phase 2 trial
+3 more records
Product overview1 text field

Helus Pharma (formerly Cybin Inc.) is a clinical-stage pharmaceutical company pioneering novel serotonergic agonists for mental health treatments. The company operates two lead drug programs: HLP003 in Phase 3 for major depressive disorder (FDA Breakthrough Designation) and HLP004 in Phase 2 for generalized anxiety disorder. The company also acquired SPL026 (synthetic DMT) from Small Pharma, which demonstrated Phase 2a efficacy for MDD. The technology platform focuses on creating novel delivery formulations designed to support consistent administration and reduce variability of acute effects.

Product and service4 records
1HLP003
CategoryLead drug program
Description

Proprietary deuterated psilocybin analog (novel serotonergic agonist) in Phase 3 APPROACH trial as adjunctive treatment for major depressive disorder; FDA Breakthrough Therapy Designation granted; topline data expected Q4 2026.

2HLP004
CategoryLead drug program
Description

Proprietary deuterated DMT analog (novel serotonergic agonist) for generalized anxiety disorder; Phase 2 study enrollment completed.

3SPL026
CategoryAcquired drug program
Description

Synthetic DMT (dimethyltryptamine) drug candidate acquired via the 2023 Small Pharma acquisition; Phase 2a data showed a statistically significant 7.35-point reduction in MADRS scores vs placebo at two weeks, with antidepressant effects sustained up to three months, supported by a 25-minute treatment profile.

4Novel Serotonergic Agonist Platform
CategoryTechnology platform
Description

Proprietary drug development platform leveraging synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, combined with novel delivery formulations intended to support consistent administration and reduce variability of acute effects.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Commercial-stage CNS biopharmaceutical company with Zurzuvae (zuranolone) approved for postpartum depression and ongoing MDD programs. Comparable as a broader CNS-focused commercial-stage peer, validating the commercial pathway for novel neuropsychiatric therapies.

2MindMed
TypeDirect peer
Description

Clinical-stage psychedelic medicine company developing LSD and psilocybin analogs for anxiety, ADHD, and other CNS indications. Directly comparable to Helus Pharma in modality (psychedelic-derived CNS therapeutics), indication overlap (MDD/anxiety), and clinical-stage status.

3atai Life Sciences
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic therapies for mental health, including MDD and anxiety. Comparable in business model (clinical-stage CNS drug development), platform breadth, and capital base, with substantial backing from founders and institutional investors.

TypeDirect peer
Description

Private clinical-stage psychedelic drug developer focused on depression and other CNS indications, backed by the Beckley Foundation. Direct peer in psychedelic CNS therapeutics with overlapping mechanisms and similar development-stage positioning.

TypeDirect peer
Description

Clinical-stage psychedelic and CNS therapeutics developer pursuing depression and anxiety indications. Notably, Helus Pharma's former CEO Doug Drysdale joined BetterLife as Executive Chairman in 2026, signaling overlap in leadership networks and a comparable therapeutic focus.

TypeDirect peer
Description

Clinical-stage company developing DMT-based therapies (GH001) for treatment-resistant depression. Direct comparable to Helus's SPL026 program in modality (synthetic DMT) and indication (TRD/MDD), with a similar inhaled/single-session administration model.

TypeDirect peer
Description

Late-stage psilocybin therapy developer for treatment-resistant depression, with completed Phase 3 program. Closest direct competitor to HLP003 in MDD with similar mechanism and Breakthrough-like regulatory engagement, and a comparable specialty CNS commercialization model.

TypeBroad incumbent
Description

Diversified pharmaceutical incumbent whose Janssen unit markets Spravato (esketamine), the first FDA-approved psychedelic-adjacent therapy for treatment-resistant depression. Comparable as a reference commercial model for clinic-administered psychedelic-class depression therapy and pricing/access benchmarks.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cybin

Neuropsychiatric Therapeuticscybin.com

Helus Pharma (formerly Cybin Inc.) is a clinical-stage pharmaceutical company developing deuterated psilocybin and DMT analogs (HLP003, HLP004) as novel serotonergic agonists for major depressive disorder and generalized anxiety disorder, with FDA Breakthrough Therapy Designation and Phase 3 data expected Q4 2026.

What Cybin does

Helus Pharma (formerly Cybin Inc.) is a clinical-stage neuropsychiatric pharmaceutical company developing deuterated psychedelic-based therapeutics for mental health conditions. Founded in 2019 in Toronto, Canada, and publicly traded on Nasdaq and Cboe Canada under ticker HELP, the company operates two lead drug programs: HLP003, a deuterated psilocybin analog in Phase 3 clinical trials for adjunctive treatment of major depressive disorder (MDD), which has received FDA Breakthrough Therapy Designation, and HLP004, a deuterated DMT analog that has completed Phase 2 enrollment for generalized anxiety disorder (GAD). The company also retains SPL026, a synthetic DMT candidate acquired through the 2023 Small Pharma acquisition, which demonstrated a 7.35-point MADRS reduction versus placebo in Phase 2a trials.

The company's core technology platform is built on novel serotonergic agonists (NSAs)—synthetic molecules engineered to activate serotonin pathways believed to promote neuroplasticity—combined with proprietary drug delivery formulations designed to reduce inter-individual variability of acute effects and shorten clinic time. The intellectual property portfolio includes 350+ pending patent applications and 100+ granted patents protecting both the molecular architecture and delivery mechanisms. The FDA Breakthrough Therapy Designation for HLP003 provides an accelerated regulatory pathway, with Phase 3 APPROACH trial topline data expected in Q4 2026.

Helus Pharma is currently pre-revenue, operating across Canada, the United States, the United Kingdom, and Ireland, with a research collaboration with Imperial College London. The company maintains approximately $195 million in cash as of December 2025 with no financial debt, supplemented by a $100 million at-the-market equity program through Cantor Fitzgerald and a ~$50 million underwritten public offering completed in June 2026, providing approximately 21 months of runway against an ~$114 million annual burn. The intended go-to-market model upon regulatory approval involves traditional pharmaceutical wholesale distribution, specialty pharmacy networks, and direct physician engagement with healthcare providers and psychiatric clinics, with analyst coverage (Jefferies, HC Wainwright) maintaining Buy ratings.

Cybin firmographics

Firmographics
Name
Cybin
Legal name
Cybin Inc.
Website
https://cybin.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Helus Pharma (formerly Cybin Inc.) is a clinical-stage pharmaceutical company developing deuterated psilocybin and DMT analogs (HLP003, HLP004) as novel serotonergic agonists for major depressive disorder and generalized anxiety disorder, with FDA Breakthrough Therapy Designation and Phase 3 data expected Q4 2026.
Ownership category
akta.pro rank

Cybin industry classification

Industry
Product category
Neuropsychiatric Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Psychedelic therapeutics
  • Neuropsychiatric drugs
  • Serotonergic agonists
  • Depression treatment
  • Anxiety treatment

Where Cybin is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices4 records

Markets served

Cybin business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Sales: Currently pre-revenue. The company is a clinical-stage neuropsychiatry company developing psychedelic-based treatments for mental health conditions. If HLP003 and HLP004 receive regulatory approval, the company would generate revenue through prescription drug sales to patients with major depressive disorder and generalized anxiety disorder.
  2. Future Licensing Royalties: Potential licensing agreements for proprietary compounds and delivery technologies to pharmaceutical partners in different geographic regions.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Cybin product offering

Product offering

Core offering

Cybin (operating as Helus Pharma) is a clinical-stage pharmaceutical company developing proprietary deuterated psilocybin and DMT analogs—branded HLP003 and HLP004—as adjunctive therapies for major depressive disorder and generalized anxiety disorder. The company also holds SPL026, a synthetic DMT candidate acquired from Small Pharma, and is advancing a proprietary drug delivery platform designed to reduce variability of acute effects and shorten in-clinic administration time.

Product overview

Helus Pharma (formerly Cybin Inc.) is a clinical-stage pharmaceutical company pioneering novel serotonergic agonists for mental health treatments. The company operates two lead drug programs: HLP003 in Phase 3 for major depressive disorder (FDA Breakthrough Designation) and HLP004 in Phase 2 for generalized anxiety disorder. The company also acquired SPL026 (synthetic DMT) from Small Pharma, which demonstrated Phase 2a efficacy for MDD. The technology platform focuses on creating novel delivery formulations designed to support consistent administration and reduce variability of acute effects.

Differentiator

Problem solved

Functional benefit

Products and services

  • HLP003 Proprietary deuterated psilocybin analog (novel serotonergic agonist) in Phase 3 APPROACH trial as adjunctive treatment for major depressive disorder; FDA Breakthrough Therapy Designation granted; topline data expected Q4 2026.
  • HLP004 Proprietary deuterated DMT analog (novel serotonergic agonist) for generalized anxiety disorder; Phase 2 study enrollment completed.
  • SPL026 Synthetic DMT (dimethyltryptamine) drug candidate acquired via the 2023 Small Pharma acquisition; Phase 2a data showed a statistically significant 7.35-point reduction in MADRS scores vs placebo at two weeks, with antidepressant effects sustained up to three months, supported by a 25-minute treatment profile.
  • Novel Serotonergic Agonist Platform Proprietary drug development platform leveraging synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, combined with novel delivery formulations intended to support consistent administration and reduce variability of acute effects.

Quantifiable outcome

  • ~23-point reduction in MADRS score at 12 months with 100% response rate and 71% remission rate in Phase 2 trial
  • +3 more outcomes

Companies that use Cybin

Customer profile

Segments3 records

Ideal customer profiles2 records

Cybin technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cybin partnerships and signals

Strategic signal

Scale indicators12 records

Recent moves8 records

Expansion highlights5 records

Cybin competitors and assessment

Company assessment

Broad incumbents

  • Sage Therapeutics: Commercial-stage CNS biopharmaceutical company with Zurzuvae (zuranolone) approved for postpartum depression and ongoing MDD programs. Comparable as a broader CNS-focused commercial-stage peer, validating the commercial pathway for novel neuropsychiatric therapies.
  • Johnson & Johnson: Diversified pharmaceutical incumbent whose Janssen unit markets Spravato (esketamine), the first FDA-approved psychedelic-adjacent therapy for treatment-resistant depression. Comparable as a reference commercial model for clinic-administered psychedelic-class depression therapy and pricing/access benchmarks.

Direct peers

  • MindMed: Clinical-stage psychedelic medicine company developing LSD and psilocybin analogs for anxiety, ADHD, and other CNS indications. Directly comparable to Helus Pharma in modality (psychedelic-derived CNS therapeutics), indication overlap (MDD/anxiety), and clinical-stage status.
  • atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic therapies for mental health, including MDD and anxiety. Comparable in business model (clinical-stage CNS drug development), platform breadth, and capital base, with substantial backing from founders and institutional investors.
  • Beckley Psytech: Private clinical-stage psychedelic drug developer focused on depression and other CNS indications, backed by the Beckley Foundation. Direct peer in psychedelic CNS therapeutics with overlapping mechanisms and similar development-stage positioning.
  • BetterLife Pharma: Clinical-stage psychedelic and CNS therapeutics developer pursuing depression and anxiety indications. Notably, Helus Pharma's former CEO Doug Drysdale joined BetterLife as Executive Chairman in 2026, signaling overlap in leadership networks and a comparable therapeutic focus.
  • GH Research: Clinical-stage company developing DMT-based therapies (GH001) for treatment-resistant depression. Direct comparable to Helus's SPL026 program in modality (synthetic DMT) and indication (TRD/MDD), with a similar inhaled/single-session administration model.
  • Compass Pathways: Late-stage psilocybin therapy developer for treatment-resistant depression, with completed Phase 3 program. Closest direct competitor to HLP003 in MDD with similar mechanism and Breakthrough-like regulatory engagement, and a comparable specialty CNS commercialization model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cybin social profiles

Digital presence

Cybin compliance and trust

Trust signal

Compliance1 record

Cybin financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cybin leadership team

Management profile

Number of profiles

Profiles4 records

Cybin subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cybin funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cybin M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cybin

What does Cybin do?

Cybin (operating as Helus Pharma) is a clinical-stage pharmaceutical company developing proprietary deuterated psilocybin and DMT analogs—branded HLP003 and HLP004—as adjunctive therapies for major depressive disorder and generalized anxiety disorder. The company also holds SPL026, a synthetic DMT candidate acquired from Small Pharma, and is advancing a proprietary drug delivery platform designed to reduce variability of acute effects and shorten in-clinic administration time.

Is Cybin a public or private company?

Cybin is a public company. It is classified as public and is currently operating.

When was Cybin founded?

Cybin was founded in 2019. It employs 101 to 250 people.

Where is Cybin based?

Cybin is headquartered in Toronto, Canada, in the North America region.

How does Cybin make money?

Two revenue lines are on record. Pharmaceutical Drug Sales are the primary driver. The others are future Licensing Royalties.

Who are Cybin's main competitors?

Broad incumbents on record are Sage Therapeutics and Johnson & Johnson. Direct peers are MindMed, atai Life Sciences, Beckley Psytech, BetterLife Pharma, GH Research and Compass Pathways.

Does Cybin have an API?

No public API is recorded for Cybin.

What industry is Cybin in?

Cybin's product category is Neuropsychiatric Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsCybin (NASDAQ:HELP) Stock Rating Upgraded by Wall Street ZenWall Street Zen upgraded Cybin from a strong sell to a sell rating. Analysts have a consensus Buy rating with a $46.33 price target, and Cybin reported a loss of $0.91 EPS, missing estimates. Insiders bought 688,000 shares over the past 90 days.MarketBeatWealthPlan Investment Management LLC Makes New $1.27 Million Investment in Cybin Inc. $HELPWealthPlan Investment Management LLC acquired a new position in Cybin Inc., buying 103,500 shares worth about $1.27 million in Q3. The fund now holds roughly 0.13% of the company, and insiders bought 688,000 shares in the last 90 days. Analysts rate Cybin a Buy with an average price target of $46.33.American Banking and Market NewsCybin Inc. (NASDAQ:HELP) Stock Has Consensus Target Price of $46.33Cybin Inc. shares have a consensus "Buy" rating from six analysts, with an average price target of $46.33. The stock opened at $10.38, and insiders purchased 688,000 shares in the last 90 days. Analysts predict a -2.95 EPS for the current fiscal year.Markets DailyCybin Inc. (HELP) – What Are Researchers Saying About This Stock?Cybin Inc. received an average "Buy" rating from six analysts with a $46.33 price target. The stock opened at $11.80, and insiders bought 200,000 shares at $12.47 each. Analysts expect a -2.95 EPS for the year.MarketBeatCybin Inc. (NASDAQ:HELP) Stock Has Average Target Price of $46.33Cybin Inc. has a consensus Buy rating with an average price target of $46.33. Insiders Eric H. L. So and CFO Greg Cavers bought shares, and the company reported a Q2 loss of $0.91 per share, missing the consensus estimate of $0.80. Analysts predict a current-year EPS of -$2.95.Markets DailyCybin (NASDAQ:HELP) Cut to “Strong Sell” at Wall Street ZenWall Street Zen cut Cybin from a sell to a strong sell rating. Analysts have an average Buy rating with a $46.33 price target, and Cybin reported a loss of $0.91 EPS, missing estimates. Insiders bought 688,000 shares in the last three months.American Banking and Market NewsCybin (NASDAQ:HELP) Downgraded by Wall Street Zen to Strong SellWall Street Zen downgraded Cybin to a strong sell rating, while Barclays and Wells Fargo gave overweight ratings with price targets. Insiders Paul Glavine and Eric So each bought 100,000 shares on September 8th, and institutional investors own 17.94% of the stock.Investing.comCybin rebrands to Helus Pharma, ticker symbol unchangedCybin Inc. completed its legal name change to Helus Pharma Inc. on Tuesday, with the rebrand approved by shareholders at the annual meeting on September 22, 2026. The company is developing HLP003, a Phase 3 compound for major depressive disorder, which has received Breakthrough Therapy Designation from the FDA.The future of tradingCybin holds annual, special shareholder meeting; name change set for Oct. 1Cybin held its annual and special shareholder meeting on Sept. 22, 2026, where shareholders approved a plan to set the board size at eight directors. Investors also endorsed changing the legal name to Helus Pharma, effective Oct. 1, 2026, and appointed Zeifmans as auditor until the next annual meeting.The future of tradingCybin appoints Zeifmans as auditor after shareholder voteCybin shareholders voted to appoint Zeifmans as auditor at the Sept. 22, 2026 annual and special meeting. The vote tallies showed 46,084,004 shares in favor and 368,593 withheld.